Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

Martin Inzinger; Katharina Wippel-Slupetzky; Wolfgang Weger; Leo Richter; Alexander Mlynek; Barbara Fleischander; Christine Scheurecker; Nikolaus Sandor; Daniela Mairhofer; Paul G Sator; Sabine Moser-Oberthaler; Nina Häring; Petra Viznerova; Clemens Painsi; Adrian Tanew; Peter Ponholzer; Rafaella Tatarski; Wilhelm Brenner; Georg Stingl; Wolfgang Salmhofer; Klemens Rappersberger; Georg Klein; Werner Saxinger; Josef Auböck; Claudia Kölli; Franz Trautinger; Andreas Steiner; Gudrun Ratzinger; Robert Strohal; Elisabeth Riedl; Bernhard Lange-Asschenfeldt; Hubert Pehamberger; Beatrix Volc-Platzer; Sylvia Selhofer; Franz Josef Legat; Robert Müllegger; Norbert Reider; Matthias Schmuth; Helmut Hintner; Angelika Hofer; Alexandra Gruber-Wackernagel; Werner Aberer; Franz Quehenberger; Peter Wolf

doi:10.2340/00015555-2214

Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

Martin Inzinger
, Katharina Wippel-Slupetzky
, Wolfgang Weger
, Leo Richter
, Alexander Mlynek
, Barbara Fleischander
, Christine Scheurecker
, Nikolaus Sandor
, Daniela Mairhofer
, Paul G Sator
, Sabine Moser-Oberthaler
, Nina Häring
, Petra Viznerova
, Clemens Painsi
, Adrian Tanew
, Peter Ponholzer
, Rafaella Tatarski
, Wilhelm Brenner
, Georg Stingl
, Wolfgang Salmhofer

Klemens Rappersberger, Georg Klein, Werner Saxinger, Josef Auböck, Claudia Kölli, Franz Trautinger, Andreas Steiner, Gudrun Ratzinger, Robert Strohal, Elisabeth Riedl, Bernhard Lange-Asschenfeldt, Hubert Pehamberger, Beatrix Volc-Platzer, Sylvia Selhofer, Franz Josef Legat, Robert Müllegger, Norbert Reider, Matthias Schmuth, Helmut Hintner, Angelika Hofer, Alexandra Gruber-Wackernagel, Werner Aberer, Franz Quehenberger, Peter Wolf

Division of Dermatology and Venereology (University Hospital St. Pölten)

Research output: Journal article (peer-reviewed) › Journal article

39 Citations (Scopus)

Abstract

This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.

Original language	English
Pages (from-to)	207-212
Number of pages	6
Journal	Acta Dermato-Venereologica
Volume	96
Issue number	2
DOIs	https://doi.org/10.2340/00015555-2214
Publication status	Published - Feb 2016

Keywords

Activities of Daily Living
Adolescent
Adult
Aged
Aged, 80 and over
Austria
Biological Products/adverse effects
Female
Humans
Immunosuppressive Agents/adverse effects
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Middle Aged
Proportional Hazards Models
Psoriasis/diagnosis
Registries
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Young Adult

Access to Document

10.2340/00015555-2214

Cite this

Inzinger, M., Wippel-Slupetzky, K., Weger, W., Richter, L., Mlynek, A., Fleischander, B., Scheurecker, C., Sandor, N., Mairhofer, D., Sator, P. G., Moser-Oberthaler, S., Häring, N., Viznerova, P., Painsi, C., Tanew, A., Ponholzer, P., Tatarski, R., Brenner, W., Stingl, G., ... Wolf, P. (2016). Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. Acta Dermato-Venereologica, 96(2), 207-212. https://doi.org/10.2340/00015555-2214

@article{257ca723fa2d414a8a4566bdc6d24778,

title = "Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria",

abstract = "This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6\%, 56.0\%, and 22.6\%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. ",

keywords = "Activities of Daily Living, Adolescent, Adult, Aged, Aged, 80 and over, Austria, Biological Products/adverse effects, Female, Humans, Immunosuppressive Agents/adverse effects, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Psoriasis/diagnosis, Registries, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists \& inhibitors, Young Adult",

author = "Martin Inzinger and Katharina Wippel-Slupetzky and Wolfgang Weger and Leo Richter and Alexander Mlynek and Barbara Fleischander and Christine Scheurecker and Nikolaus Sandor and Daniela Mairhofer and Sator, \{Paul G\} and Sabine Moser-Oberthaler and Nina H{\"a}ring and Petra Viznerova and Clemens Painsi and Adrian Tanew and Peter Ponholzer and Rafaella Tatarski and Wilhelm Brenner and Georg Stingl and Wolfgang Salmhofer and Klemens Rappersberger and Georg Klein and Werner Saxinger and Josef Aub{\"o}ck and Claudia K{\"o}lli and Franz Trautinger and Andreas Steiner and Gudrun Ratzinger and Robert Strohal and Elisabeth Riedl and Bernhard Lange-Asschenfeldt and Hubert Pehamberger and Beatrix Volc-Platzer and Sylvia Selhofer and Legat, \{Franz Josef\} and Robert M{\"u}llegger and Norbert Reider and Matthias Schmuth and Helmut Hintner and Angelika Hofer and Alexandra Gruber-Wackernagel and Werner Aberer and Franz Quehenberger and Peter Wolf",

note = "Publisher Copyright: {\textcopyright} 2016 The Authors.",

year = "2016",

month = feb,

doi = "10.2340/00015555-2214",

language = "English",

volume = "96",

pages = "207--212",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden AB",

number = "2",

}

Inzinger, M, Wippel-Slupetzky, K, Weger, W, Richter, L, Mlynek, A, Fleischander, B, Scheurecker, C, Sandor, N, Mairhofer, D, Sator, PG, Moser-Oberthaler, S, Häring, N, Viznerova, P, Painsi, C, Tanew, A, Ponholzer, P, Tatarski, R, Brenner, W, Stingl, G, Salmhofer, W, Rappersberger, K, Klein, G, Saxinger, W, Auböck, J, Kölli, C, Trautinger, F, Steiner, A, Ratzinger, G, Strohal, R, Riedl, E, Lange-Asschenfeldt, B, Pehamberger, H, Volc-Platzer, B, Selhofer, S, Legat, FJ, Müllegger, R, Reider, N, Schmuth, M, Hintner, H, Hofer, A, Gruber-Wackernagel, A, Aberer, W, Quehenberger, F & Wolf, P 2016, 'Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria', Acta Dermato-Venereologica, vol. 96, no. 2, pp. 207-212. https://doi.org/10.2340/00015555-2214

Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. / Inzinger, Martin; Wippel-Slupetzky, Katharina; Weger, Wolfgang et al.
In: Acta Dermato-Venereologica, Vol. 96, No. 2, 02.2016, p. 207-212.

Research output: Journal article (peer-reviewed) › Journal article

TY - JOUR

T1 - Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions

T2 - Report from the Psoriasis Registry Austria

AU - Inzinger, Martin

AU - Wippel-Slupetzky, Katharina

AU - Weger, Wolfgang

AU - Richter, Leo

AU - Mlynek, Alexander

AU - Fleischander, Barbara

AU - Scheurecker, Christine

AU - Sandor, Nikolaus

AU - Mairhofer, Daniela

AU - Sator, Paul G

AU - Moser-Oberthaler, Sabine

AU - Häring, Nina

AU - Viznerova, Petra

AU - Painsi, Clemens

AU - Tanew, Adrian

AU - Ponholzer, Peter

AU - Tatarski, Rafaella

AU - Brenner, Wilhelm

AU - Stingl, Georg

AU - Salmhofer, Wolfgang

AU - Rappersberger, Klemens

AU - Klein, Georg

AU - Saxinger, Werner

AU - Auböck, Josef

AU - Kölli, Claudia

AU - Trautinger, Franz

AU - Steiner, Andreas

AU - Ratzinger, Gudrun

AU - Strohal, Robert

AU - Riedl, Elisabeth

AU - Lange-Asschenfeldt, Bernhard

AU - Pehamberger, Hubert

AU - Volc-Platzer, Beatrix

AU - Selhofer, Sylvia

AU - Legat, Franz Josef

AU - Müllegger, Robert

AU - Reider, Norbert

AU - Schmuth, Matthias

AU - Hintner, Helmut

AU - Hofer, Angelika

AU - Gruber-Wackernagel, Alexandra

AU - Aberer, Werner

AU - Quehenberger, Franz

AU - Wolf, Peter

PY - 2016/2

Y1 - 2016/2

N2 - This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.

AB - This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.

KW - Activities of Daily Living

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Austria

KW - Biological Products/adverse effects

KW - Female

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Intention to Treat Analysis

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Psoriasis/diagnosis

KW - Registries

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha/antagonists & inhibitors

KW - Young Adult

UR - https://www.scopus.com/pages/publications/84949023342

U2 - 10.2340/00015555-2214

DO - 10.2340/00015555-2214

M3 - Journal article

C2 - 26271044

SN - 0001-5555

VL - 96

SP - 207

EP - 212

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 2

ER -

Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this